Chemotherapy-related moderate or severe neutropenia
Conditions
Interventions
Sponsors
Harbin Institute of Hematology and Oncology; Cancer Center of the Whole Army of the Eastern Theater General hospital; Cancer Prevention and Treatment Center of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients willing to sign informed consent and voluntarily join the study; 2. Patients with non myeloid malignant tumor (including solid tumor and malignant blood tumor) confirmed by pathology or Histocytology; 3. Patients who were judged by the researchers to be able to receive the administration of tiopefigeristine; 4. Patients >= 18 years old.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who are allergic to thiopefigeristine, pegylated recombinant human granulocyte stimulating factor, recombinant human granulocyte stimulating factor and other preparations expressed in E.coli; 3. Other situations that are not suitable for inclusion in the study are judged by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| RDI%;incidence of Grade 3 and Grade 4 Neutropenia in Cycle 1;incidence of FN in Cycle 1;incidence of Grade 3 and Grade 4 Neutropenia in all cycle;incidence of FN in all cycle;Length of hospital stay due to FN; | — |
Countries
China
Contacts
Public ContactMa Jun, Qin Shukui, Xu Ruihua
Harbin Institute of Hematology and Oncology; Cancer Center of the Whole Army of the Eastern Theater General hospital; Cancer Prevention and Treatment Center of Sun Yat-Sen University
Outcome results
None listed